Asia Pacific Women’s Health Market Size & Outlook
Asia Pacific women’s health market, 2018-2030 (US$M)
Related Markets
Asia Pacific women’s health market highlights
- The Asia Pacific women’s health market generated a revenue of USD 10,404.5 million in 2023.
- The market is expected to grow at a CAGR of 7.7% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 10,404.5 million |
| Market revenue in 2030 | USD 17,433.6 million |
| Growth rate | 7.7% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 23.5% of the global women’s health market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 17,433.6 million by 2030.
Contraceptives was the largest segment with a revenue share of 35.6% in 2023. Horizon Databook has segmented the Asia Pacific women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to witness substantial growth during the forecast period owing to the presence of a large population and an increase in the demand for contraceptives. In Asia Pacific, India and China are highly populated countries. The rise in government initiatives undertaken to control their population growth is expected to positively impact the women’s health market.
Asia Pacific consists of a blend of developing and developed economies. Increasing healthcare expenditure in the region is anticipated to fuel market growth. The increasing geriatric population and rising awareness of women’s health are among the major factors driving the market in this region.
According to an NCBI report in 2019, an estimated 15% of women in Asia Pacific were affected by endometriosis, whereas in Western countries, this prevalence was about 5% to 10%. Furthermore, various government agencies, such as the Asia Pacific Menopause Federation and the International Osteoporosis Foundation.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific women’s health market size, by country, 2018-2030 (US$M)
Asia Pacific Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
